spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  ocrelizumab 

 HSMN NewsFeed - 25 Jun 2024
Halozyme Announces Roche's OCREVUS(R) SC with ENHANZE(R) Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 5 Mar 2018
Aridis Pharmaceuticals, Inc. Appoints Wolfgang Dummer, M.D., Ph.D., as Chief Medical Officer, and Mitchell H. Rosner, Ph.D. as Vice President of Quality
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 29 Mar 2017
FDA Approves Genentech’s OCREVUS(TM) (Ocrelizumab) for Relapsing and Primary Progressive Forms of Multiple Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 22 Dec 2016
Positive Phase III Results of Genentech’s Investigational Medicine OCREVUS(TM) (Ocrelizumab) Published in New England Journal of Medicine
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Jun 2016
FDA Grants Priority Review for Genentech’s OCREVUS(TM) (ocrelizumab) Biologics License Application
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 17 Feb 2016
FDA Grants Breakthrough Therapy Designation for Genentech’s Investigational Medicine Ocrelizumab in Primary Progressive Multiple Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 30 Jun 2015
Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif(R)) in Two Phase III Studies in Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 30 Jun 2011
Sheila Gujrathi, M.D. Named Chief Medical Officer of Receptos
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Mar 2011
KaloBios Announces Two Significant Additions to Its Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 May 2010
Roche and Biogen Idec Announce Their Decision to Discontinue the ocrelizumab Clinical Development Programme in Patients with Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 11 Dec 2009
Genentech and Biogen Idec Announce Positive Results From First Phase III Trial of Ocrelizumab in Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 27 Jul 2009
Halozyme Therapeutics Appoints Jonathan Leff, M.D. as Vice President, Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Dec 2008
MorphoSys Appoints Dr. Arndt Schottelius as Chief Development Officer and Member of the Management Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Jun 2007
Latest Data Show MabThera(R) Provides Significant and Sustained Relief From Signs and Symptoms of Rheumatoid Arthritis
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 1

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 1 additional stories matching:
ocrelizumab
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.